Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of... View Article
New member | Substra Foundation
Substra Foundation is an independent nonprofit organization dedicated to fostering the development of trustworthy data science ecosystems. It promotes, protects... View Article
BHealthCare raises € 1.5 M to finalise development of its robotic blood sampling platform, HEIVA™
BHealthCare, a MedTech specialising in the development of next-generation robotic solutions to provide more reliable peripheral vascular access, has announced... View Article
The “France Relance” stimulus package: the Healthcare Clusters network proposes three options to guarantee French healthcare sovereignty
Improve access to equity by launching novel specialised investment funds Support research and innovation by issuing calls for projects with... View Article
A Nanofitins production unit: a project run by Affilogic, winner of the industrial relocation plan
Affilogic, a company specialising in the discovery and development of Nanofitins® for biotherapeutic applications, is one of the 31 projects... View Article
Atlanpole Biotherapies | Customized services
Broadly speaking, cluster members are offered customized services that open up a path to European funding aimed at boosting innovation... View Article
Valneva prepares for Potential US IPO
Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, today announced that it will convene an Extraordinary General Meeting (EGM)... View Article
Hemarina and Brest University Hospital (CHRU de Brest): OxyOp2 clinical trial proceeds successfully in all french transplant centers
Brest University Hospital and Hemarina, a biotech company based in Brittany, announced today they have successfully topped the 100 people involved in... View Article
New member | Imagin VR
Imagin VR is a company specialised in designing immersive, interactive and collaborative Virtual Reality devices, as well as developing VR... View Article
Ose Immunotherapeutics announces a successful capital increase of €18.6M by private placement
Offering close to 2.5 times oversubscribed versus the initial minimum target OSE IMMUNOTHERAPEUTICS (Euronext – FR0012127173 – OSE or the “Company”), an... View Article